PL408649A1 - Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy - Google Patents

Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy

Info

Publication number
PL408649A1
PL408649A1 PL408649A PL40864914A PL408649A1 PL 408649 A1 PL408649 A1 PL 408649A1 PL 408649 A PL408649 A PL 408649A PL 40864914 A PL40864914 A PL 40864914A PL 408649 A1 PL408649 A1 PL 408649A1
Authority
PL
Poland
Prior art keywords
protein
influenza viruses
vaccine antigen
vaccine
haemagglutinin protein
Prior art date
Application number
PL408649A
Other languages
English (en)
Other versions
PL235555B1 (pl
Inventor
Violetta Sączyńska
Agnieszka Romanik
Katarzyna Florys
Violetta Cecuda-Adamczewska
Małgorzata Kęsik-Brodacka
Grażyna Płucienniczak
Andrzej Płucienniczak
Piotr Borowicz
Natalia Łukasiewicz
Iwona Sokołowska
Diana Mikiewicz
Agnieszka Sobolewska
Piotr Baran
Józef Kapusta
Michał Odrowąż-Sypniewski
Anna Bierczyńska-Krzysik
Zenon Minta
Krzysztof Śmietanka
Monika Olszewska
Bogusław Szewczyk
Original Assignee
Instytut Biotechnologii i Antybiotyków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biotechnologii i Antybiotyków filed Critical Instytut Biotechnologii i Antybiotyków
Priority to PL408649A priority Critical patent/PL235555B1/pl
Priority to PCT/PL2015/050025 priority patent/WO2015199564A1/en
Priority to EP15744381.3A priority patent/EP3160501B1/en
Priority to US15/320,484 priority patent/US10398770B2/en
Publication of PL408649A1 publication Critical patent/PL408649A1/pl
Publication of PL235555B1 publication Critical patent/PL235555B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Wynalazek dotyczy białka hemaglutyniny wirusów grypy jako antygenu szczepionkowego przeciwko wirusom grypy, w szczególności białka będącego fragmentem hemaglutyniny H5 wysoko-patogennego szczepu wirusa ptasiej grypy (HPAIV) H5N1 ekspresjonowanego w bakteryjnym systemie ekspresyjnym. Białko według wynalazku jest potencjalnym składnikiem szczepionki przeciwko HPAIV H5N1, podawanej kurczętom parenteralnie lub przez błony śluzowe w obecności adiuwantów. Przedmiotem wynalazku jest również sposób otrzymywania białka szczepionkowego.
PL408649A 2014-06-24 2014-06-24 Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu PL235555B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL408649A PL235555B1 (pl) 2014-06-24 2014-06-24 Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
PCT/PL2015/050025 WO2015199564A1 (en) 2014-06-24 2015-06-24 Influenza virus hemagglutinin protein as a vaccine antigen
EP15744381.3A EP3160501B1 (en) 2014-06-24 2015-06-24 Influenza virus hemagglutinin protein as a vaccine antigen
US15/320,484 US10398770B2 (en) 2014-06-24 2015-06-24 Influenza virus hemagglutinin protein as a vaccine antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL408649A PL235555B1 (pl) 2014-06-24 2014-06-24 Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu

Publications (2)

Publication Number Publication Date
PL408649A1 true PL408649A1 (pl) 2016-01-04
PL235555B1 PL235555B1 (pl) 2020-09-07

Family

ID=53761469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL408649A PL235555B1 (pl) 2014-06-24 2014-06-24 Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu

Country Status (4)

Country Link
US (1) US10398770B2 (pl)
EP (1) EP3160501B1 (pl)
PL (1) PL235555B1 (pl)
WO (1) WO2015199564A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CA2849434A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
WO2017210445A1 (en) * 2016-06-03 2017-12-07 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042001A1 (en) 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
CN106237316A (zh) 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
PL216037B1 (pl) 2006-06-09 2014-02-28 Inst Biotechnologii I Antybiotykow Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CA2805741C (en) * 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
GB201116416D0 (en) * 2011-09-23 2011-11-02 Isis Innovation Composition
PL220281B1 (pl) * 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
PL238555B1 (pl) * 2013-12-20 2021-09-06 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5

Also Published As

Publication number Publication date
EP3160501A1 (en) 2017-05-03
WO2015199564A1 (en) 2015-12-30
US20170165352A1 (en) 2017-06-15
PL235555B1 (pl) 2020-09-07
US10398770B2 (en) 2019-09-03
EP3160501B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
PL408649A1 (pl) Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
BR112015030582A2 (pt) Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
AU2014310935B2 (en) Combination vaccine
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112017006680A2 (pt) variantes de vírus influenza a
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
EA201290897A1 (ru) Вакцины для пандемического гриппа
MX2022006561A (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
AU2011280259A8 (en) Influenza vaccine
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
BR112018014042A2 (pt) vírus do tipo orthomyxo da tilápia.
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
EA201400235A1 (ru) Вакцины против гриппа на основе н5
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
MX2019007924A (es) Vacunas contra la influenza.